



2023 Snapshot of Pharmacy Compounding Survey

Joey Mattingly, PharmD, MBA, PhD

Associate Professor
University of Utah College of Pharmacy

1

Research Team

Grace LaFleur, PharmD

Assistant Professor
 University of Utah College of Pharmacy
grace.lafleur@pharm.utah.edu

Joey Mattingly, PharmD, MBA, PhD

Associate Professor & Vice Chair of Research
 University of Utah College of Pharmacy
joey.mattingly@utah.edu



L. S. SKAGGS PHARMACY INSTITUTE



2

Funding and Conflicts of Interest

Project Funding: This project was supported by the Alliance for Pharmacy Compounding (**APC**)

Unrelated Conflicts of Interest: Dr. Mattingly discloses research funding from the Food & Drug Administration (**FDA**) unrelated to material presented today and **spouse** is also a full-time employee of the FDA.

Dr. Mattingly is also the founder and CEO of **Drugscope, Inc.** that provides data analysis and research services for Workers' compensation plans.

Dr. Mattingly has received consulting fees from Arnold Ventures, the Pharmaceutical Care Management Association (**PCMA**), and Pharmaceutical Research & Manufacturers of America (**PhRMA**) related to **drug pricing policy**. Additionally, Dr. Mattingly was an unpaid advisor to the Centers for Medicare & Medicaid Services (**CMS**) for implementation of drug pricing provisions in the Inflation Reduction Act.



3

Objectives

1. Brief overview of background and survey methods.
2. Review of preliminary results.
3. Discussion and next steps.



4

Background and Methods

Brief review of survey objectives and methods for distribution and analysis.



5

Survey Background and Methods

- Last national compounding snapshot conducted in 2021 by Dr. Lance Gentry at the University of Mary Washington in Fredericksburg, Virginia.
- A research collaboration between the University of Utah, APC, Fagron, Medisca, and PCCA in the summer of 2023.
- Questions from 2021 survey were discussed and revised.
- New survey distributed in fall 2023, led by Drs. Grace LaFleur and Joey Mattingly.



6

Survey Organization

- **Section 1: Individual-level**
 - We first report descriptive statistics for all survey responses.
 - Since we did not force responses for all the questions, participants had the option of leaving a question blank.
- **Section 2: Owners and Partial Owners**
 - We then separated out all responses from those who self-reported either full or partial ownership.
- **Section 3: Pharmacy-level**
 - Finally, we created a separate analysis focusing on unique pharmacy responses.



7


Preliminary Results

- Survey was sent to **12,275** unique email addresses provided by PCCA, Medisca, and Fagron on September 28, 2023, and additional APC contacts October 10, 2023.
- Survey was closed on November 13, 2023, with **699** completed responses, for a **6% response rate** (Not every question was answered by all participants).
 - In 2021, 763 responses were used (567 from email and another 169 from flyers and APC link)
- Survey included 93 total questions.



8

Figure 1. STROBE Flow Diagram



9

Preliminary Results – Individual

Variable (N of Completed Responses)	Count	Percentage
Role (n=578)		
Pharmacist	442	76%
Technician	103	18%
Other	33	6%
Compounding Setting (n=569)		
503A	445	78%
503B	22	4%
Both 503A and 503B	48	8%
Other	54	9%
Practice Setting (n=583)		
Independent community pharmacy	416	71%
Other	60	10%
Compounding supplier/service provider	59	10%
Veterinary pharmacy practice	36	6%
503B outsourcing facility	12	2%
Unique Pharmacy		
Yes	529	76%
No (Responses from staff from same pharmacy)	170	24%

10

Preliminary Results – Individual

Pharmacist Responses

- 442 responses
- 63% male; 37% female
- Board-Certified Sterile Compounding Pharmacist (BCSCP) designation: 7%
- Owner or part-owner: 62%

Technician Responses

- 103 responses
- 24% male; 76% female
- Certified Pharmacy Technician (CPhT): 84%
- Registered Technician: 95%
- Certified Compounded Sterile Preparation Technician (CSPT): 21%



11

Issues of Concern (By % of business from compounding drugs in shortage)

1-20% Business includes Compounding Shortage Drugs

- N=22
- Semaglutide: 58%
- Amoxicillin suspension: 30%
- 503B Only*
 - Ibu or APAP suspension: 16%

>20% Business includes Compounding Shortage Drugs

- N=138
- Semaglutide: 71%
- Amoxicillin suspension: 14%
- 503B Only*
 - Ibu or APAP suspension: 20%



12

Drugs Compounded on FDA Shortage List

Belladonna & Opium Suppository	Methotrexate
Bupivacaine	Oxytocin
Desmopressin	Rifampin
Dexamethasone Sodium Phosphate	Semaglutide
Dextrose 50%	Sodium Bicarbonate
Diazepam Gel	Sucralfate
Gentamicin	Tirzepatide
Ketamine	Viscous Lidocaine



13

Owners & Partial Owner Responses *(by % of business from compounding)*

<15%

- N=70
- Cash only: 35%
- Understaffed: 17%
- Hiring RPh: 46% (difficult)
- Hiring Tech: 73% (difficult)
- Offer retirement: 70%
- Health insurance: 65%

15%-50%

- N=34
- Cash only: 42%
- Understaffed: 16%
- Hiring RPh: 54% (difficult)
- Hiring Tech: 71% (difficult)
- Offer retirement: 52%
- Health insurance: 68%

>50%

- N=120
- Cash only: 61%
- Understaffed: 26%
- Hiring RPh: 30% (difficult)
- Hiring Tech: 76% (difficult)
- Offer retirement: 72%
- Health insurance: 73%



14

Pharmacy-Level Analysis (by % of business from compounding)

<15%

- N=72
- PCAB: 1%
- NABP VPP: 0%
- URAC: 0%
- Stop hazardous: 26% (Y)
- Quality (internal): 59%
- Quality (external): 45%
- Develop Formulation: 57%

15%-50%

- N=23
- PCAB: 18%
- NABP VPP: 5%
- URAC: 0%
- Stop hazardous: 10% (Y)
- Quality (internal): 74%
- Quality (external): 79%
- Develop Formulation: 60%

>50%

- N=96
- PCAB: 27%
- NABP VPP: 11%
- URAC: 3%
- Stop hazardous: 5% (Y)
- Quality (internal): 79%
- Quality (external): 92%
- Develop Formulation: 92%

15

Compounding Formula Development

- Has your pharmacy developed its own formulations? (N=215)
 - Yes = 77%
- Where does your pharmacy get its formulations? (Select all)
 - Supplier / distributor = 93%
 - We develop our own = 69%
 - USP Monographs = 47%
 - IJPC = 46%
 - Pharmacy compounding software = 36%

16

Compounding Policy & Advocacy

Organization Engagement

- Membership
 - State association: 67%
 - APC: 41%
 - NCPA: 33%
 - APhA: 31%
 - ACA: 10%
- Events
 - Vendor webinars: 40%
 - PCCA events: 37%

Reliance for Advocacy

- What organization do you rely on for policy and advocacy related to compounding issues?
 - State Association: 74%
 - APC: 70%
 - Wholesaler: 62%
 - NCPA: 58%
 - APhA: 49%
 - ASHP: 26%



17

Limitations (Lessons learned)

- In addition to the email blasts, we'd like to work on better recruitment strategies (Thoughts from audience?)
- Should we have a different recruitment strategy for 503B?
- Open-ended questions were difficult to analyze, particularly when we wanted to evaluate things like “% of business”
- Need to develop a better way of doing a “pharmacy-level” analysis, because it is difficult to assess multiple responses from same pharmacy



18

Next Steps

- Finalize report with APC and collaborate on APC communications
- Draft peer-reviewed manuscript for select questions; ideally we would submit the paper to JAPhA
- Develop a clean, blinded dataset for use by other partners



19

Contact Information

Joey Mattingly, PharmD, MBA, PhD
joey.mattingly@utah.edu



20